Combination therapy reprogrammed the TME by increasing CD8+ cytotoxic T cell infiltration and activation, shifting the M1/M2 ratio of tumor-associated macrophages with reduction of T regulatory cell and infiltration of C-C chemokine receptor 2-positive monocyte in HCC tissue [50]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.